Look for another person calling about MannKind soon on Mad Money just so Cramer can say stay away, imo. This is getting old.
I have to believe shorts are beginning to see the writing on the wall since trusted publications are beginning to feature articles about Afrezza. See other posts today.
Great posts on this thread. To me this is evidence of the Sanofi PR machine at work. PR departments typically develop press kits with pre-written articles. Publications then put their own spin on the information and publish. Press kits will be geared to each publication's audience, so you'll see different information sent out depending on whether its a medical journal or women's magazine. To me this is more evidence of marketing beginning to take hold. Once physicians have been educated and product available at pharmacies, broad based consumer advertising will begin.
Absolutely. Christmas is coming up and FB will likely attract a good chunk of advertising.
Afrezza is in their system. This means they likely have had contact with Sanofi sales. Go to the site, type in Afrezza and your zip code.
I'd be really disappointed with a $20-25 buyout. Afrezza and technosphere are huge winners in my opinion and I want to realize their full potential be it through partnership (my preference) or buyout.
I believe the change at Sanofi and its impact on Afrezza's launch plans will be a subject of discussion during Q&A. That, of course, will be in addition to a status update from Mnkd on progress with Afrezza. I would really love it if an analyst would ask about plans for Tecnosphere.
This should be a plus for Mannkind. VC's are generally adept at thinking out of the box and identifying nascent growth opportunities. I have to believe he recognized Mannkind's potential and was behind the partnership.
He likely has signed, or will sign, a non-compete in order to get his severance package. That would make this scenario a non-starter.
Another exec. At the time shorts on the board we cackling about lack of CEO confidence in Mnkd because it wasn't the CEO on the call.